Cargando…

Different responses to anti-programmed cell death protein 1 (PD-1) immunotherapy in a patient with Lynch syndrome and metachronous urothelial and colon cancer: A case report

Lynch syndrome (LS), as a result of the germline mutations in DNA mismatch repair genes, is characterized by the increased risk of endometrium, colon, and urinary tract cancer. Individuals with this disorder may occasionally have multiple primary carcinomas. Regardless of tumor type, pembrolizumab w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Yu, Cao, Yufeng, Yuan, Mingming, Chen, Rongrong, Ji, Xue, Hu, Xingsheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781514/ https://www.ncbi.nlm.nih.gov/pubmed/31612019 http://dx.doi.org/10.3892/ol.2019.10909

Ejemplares similares

Total colectomy for multiple metachronous colon cancers in a patient with Lynch syndrome
por: Kochi, Masatoshi, et al.
Publicado: (2015)

Metachronous colon cancer risk following surgery for first primary rectal cancer in Lynch syndrome
por: Parry, S, et al.
Publicado: (2012)

Excluding Lynch syndrome in a female patient with metachronous DNA mismatch repair deficient colon- and ovarian cancer
por: Crobach, Stijn, et al.
Publicado: (2017)

A predictive model of metachronous colorectal cancer occurrence in Lynch syndrome
por: Bertario, Lucio, et al.
Publicado: (2010)

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
por: Guo, Liting, et al.
Publicado: (2017)

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer
por: Sweis, Randy F., et al.
Publicado: (2018)

Metachronous ileal cancer after surgery for ascending colon cancer in a patient with Lynch syndrome: A case report
por: Tachikawa, Yuichi, et al.
Publicado: (2021)

Lynch Syndrome: Its Impact on Urothelial Carcinoma
por: Lindner, Andrea Katharina, et al.
Publicado: (2021)

Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management
por: Shen, John, et al.
Publicado: (2018)

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
por: Abaza, Abdelrahman, et al.
Publicado: (2023)

Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
por: Núñez Abad, Martín, et al.
Publicado: (2022)

Are all metachronous multifocal urothelial carcinoma created equal?
por: Reis, Leonardo O.
Publicado: (2018)

Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD‐1/PDL‐1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer
por: Winer, Arthur, et al.
Publicado: (2019)

Molecular subtype classification of urothelial carcinoma in Lynch syndrome
por: Therkildsen, Christina, et al.
Publicado: (2018)

Early detection of metachronous bile duct cancer in Lynch syndrome: report of a case
por: Shigeyasu, Kunitoshi, et al.
Publicado: (2013)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms
por: Yin, Huihui, et al.
Publicado: (2021)

A patient with four metachronous cancers and multiple adenomatous colon polyps harboring the American Founder Lynch syndrome mutation: a case report
por: Dohany, Lindsay, et al.
Publicado: (2011)

Anti–Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis()
por: Chen, Ran, et al.
Publicado: (2016)

Effect of smoking on urothelial cancer risk in individuals with Lynch syndrome
por: Kohlmann, Wendy, et al.
Publicado: (2010)

Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy
por: Huang, Jumin, et al.
Publicado: (2022)

Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon Adenocarcinoma
por: Ibrahiem, Afaf T., et al.
Publicado: (2023)

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
por: Rosenberg, Jonathan E., et al.
Publicado: (2019)

Programmed Cell Death Protein‐1 (PD‐1)‐Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World
por: Cui, Hanzhi, et al.
Publicado: (2020)

Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma
por: Ma, Yu-Ting, et al.
Publicado: (2022)

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

PD-1 blockage combined with vaccine therapy can facilitate immune infiltration in tumor microenvironment of Lynch syndrome colon cancer
por: Ye, Kai, et al.
Publicado: (2022)

Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome
por: Donahue, Timothy F., et al.
Publicado: (2018)

Mismatch repair deficiency testing in Lynch syndrome-associated urothelial tumors
por: Rasmussen, Maria, et al.
Publicado: (2023)

Metachronous schwannoma in the colon with vestibular schwannoma
por: Jung, Eun-Joo, et al.
Publicado: (2014)

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
por: Zhu, Jason, et al.
Publicado: (2018)

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma
por: Klümper, Niklas, et al.
Publicado: (2023)

Correction: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

Corrigendum: Case report: Potential predictive value of MMR/MSI status and PD-1 expression in immunotherapy for urothelial carcinoma
por: Ma, Yu-Ting, et al.
Publicado: (2023)

Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis
por: Malik, Salim S., et al.
Publicado: (2017)

A Novel Mutation of MSH2 Gene in a Patient with Lynch Syndrome Presenting with Thirteen Metachronous Malignancies
por: Silinskaite, Ugne, et al.
Publicado: (2023)

Metachronous cutaneous squamous cell carcinoma in a young patient as the only presenting symptom to uncover Lynch syndrome with MLH1 Germline mutation
por: Khaddour, Karam, et al.
Publicado: (2020)

Risk factors and survival outcomes of metachronous contralateral upper tract urothelial carcinoma
por: Wu, Kan, et al.
Publicado: (2020)

Metachronous urothelial carcinoma in the renal pelvis, bladder, and urethra: A case report
por: Zhang, Jian-Qing, et al.
Publicado: (2023)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5h0c9ba5fhvqcn9r2fak5brsn6